EXHIBIT 99
8229 Boone Boulevard, Suite 802 COMPANY CONTACT:
Vienna, VA 22182. USA Gavin de Windt
Telephone (703) 506-9460 CEL-SCI Corporation
www.cel-sci.com (703) 506-9460
CEL-SCI REPORTS ON NYSE MKT NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN
Vienna, VA, July 19, 2013 - CEL-SCI Corporation (NYSE MKT: CVM) reported on a
communication from staff of its current listing exchange that it considered the
company to be noncompliant with certain listing requirements based on its
quarterly report for the period ended March 31, 2013. The Company was given an
opportunity to maintain its listing by submitting a plan of compliance by August
19, 2013. The Company intends to submit such a plan by August 19, 2013.
Based on the company's quarterly report on Form 10-Q for the period ended March
31, 2013, noncompliance was noted with respect to the requirement of Section
1003(a)(iv) of the Company Guide for NYSE MKT. The exchange indicated that in
order to maintain its NYSE MKT listing, a plan should be submitted by August 19,
2013 addressing regaining compliance with Section 1003(a)(iv) of the exchange's
Company Guide by September 30, 2013. Additional information and provisions
regarding the NYSE MKT requirements are found in Part 10 of its Company Guide.
The communication and compliance plan has no current effect on the listing of
the company's shares on the exchange. If the plan is not acceptable or the
company does not make sufficient progress under the plan or reestablish
compliance by September 30, 2013, then staff of the exchange may initiate
proceedings for delisting from the NYSE MKT. The company may then appeal a staff
determination to initiate such proceedings in accordance with the exchange's
Company Guide.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the
treatment of cancer and other diseases by utilizing the immune system, the
body's natural defense system. Its lead investigational therapy is Multikine
(Leukocyte Interleukin, Injection), currently being studied in a pivotal global
Phase III clinical trial. CEL-SCI is also investigating an immunotherapy
(LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a
vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing)
using its LEAPS technology platform. The investigational immunotherapy
LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu,
Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned
about the possible emergence of a new more virulent hybrid virus through the
combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has
operations in Vienna, Virginia, and in/near Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and
"expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which could
cause actual results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability to duplicate
the clinical results demonstrated in clinical studies, timely development of any
potential products that can be shown to be safe and effective, receiving
necessary regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary capital and the
risk factors set forth from time to time in CEL-SCI Corporation's SEC filings,
including but not limited to its report on Form 10-K for the year ended
September 30, 2012. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking statements which may be made to
reflect the events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.